{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-001516","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.589465+00:00","generated_at":"2026-06-20T09:38:46.916288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott Q4 sales $10.1B, full-year GAAP EPS $3.91; guides FY23 adj. EPS $4.30-4.50","bullets":["Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.03; full-year GAAP EPS $3.91, adjusted $5.34.","Full-year sales flat at $43.7B; organic growth 6.4%; COVID-testing sales $8.4B vs. $7.7B in 2021.","2023 guidance: GAAP EPS $3.05-3.25, adjusted EPS $4.30-4.50; organic growth ex-COVID high-single digits.","Quarterly dividend of $0.51 per share declared, payable Feb. 15, 2023; 51 consecutive years of increases.","FreeStyle Libre Q4 sales ~$1.1B; U.S. growth >40%; FDA approvals for Navitor TAVI and Eterna SCS."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-001516","json":"https://secwatch.observer/filing/0001628280-23-001516.json","markdown":"https://secwatch.observer/filing/0001628280-23-001516.md","text":"https://secwatch.observer/filing/0001628280-23-001516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/abt-20230125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:38:46.916288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7998107147c0e1cdb9124cc3086fa04abee689ec","claim":"ABBOTT LABORATORIES reported full year 2022 results: revenue $43.7 billion, EPS $3.91. Guidance initiated.","evidence_excerpt":"--- News Release Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook – Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion – Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent – Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 – Continues to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$43.7 billion"},{"label":"EPS","value":"$3.91"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f8e6bcf7820feff397281a0548adb6f1700b259b","claim":"ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2022 results: revenue $10.1 billion, EPS $0.59.","evidence_excerpt":"Abbott today announced financial results for the fourth quarter ended Dec. 31, 2022. • Fourth-quarter sales of $10.1 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended Dec. 31, 2022"},{"label":"Revenue","value":"$10.1 billion"},{"label":"EPS","value":"$0.59"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}